Amgen’s IMDELLTRA Gets Reduced FDA Monitoring Time
Thousand Oaks, California, U.S., September 14, 2026 Amgen announced that the U.S. Food and Drug Administration (FDA) has approved...
small cell lung cancer
Advertisement
Amgen and AstraZeneca’s IMDELLTRA-IMFINZI Improves SCLC Survival
Thousand Oaks, California, USA, September 8, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3 DeLLphi-305...
RedHill Divests Talicia to Apotex for $18 Million
Miami, Florida, August 31, 2026 RedHill Biopharma Ltd. announced that it has entered into an agreement to divest Talicia®...
IDEAYA’s IDE849 Advances Toward Phase 3 in Lung Cancer
South San Francisco, California, August 31, 2026 IDEAYA Biosciences, Inc. announced the successful completion of a U.S. Food and...
Rocket Pharmaceuticals Reports Positive RP-A501 Safety Update
CRANBURY, N.J., Aug. 3, 2026 Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients...
Advertisements
Zai Lab Receives FDA Orphan Drug Designation for Zoci
SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...
IDEAYA Showcases Darovasertib Data at ESMO 2026
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
Hansoh Pharma Reports Positive Phase III Ris-Rez SCLC Results
SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...
Zai Lab Secures EMA Support for Rare Lung Cancer Therapy
SHANGHAI & CAMBRIDGE, Mass., June 16, 2026 Zai Lab announced that the European Medicines Agency (EMA) has granted Orphan...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
Advertisement
